Q3 Earnings Forecast for BPMC Issued By Wedbush

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Stock analysts at Wedbush issued their Q3 2026 earnings per share estimates for Blueprint Medicines in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst D. Nierengarten expects that the biotechnology company will post earnings per share of $0.17 for the quarter. Wedbush has a "Outperform" rating and a $128.00 price target on the stock. The consensus estimate for Blueprint Medicines' current full-year earnings is ($1.28) per share. Wedbush also issued estimates for Blueprint Medicines' Q4 2026 earnings at $0.40 EPS.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%.

Several other equities analysts have also weighed in on BPMC. StockNews.com lowered shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a research report on Monday, March 3rd. Needham & Company LLC reissued a "buy" rating and issued a $133.00 price objective on shares of Blueprint Medicines in a report on Tuesday, April 8th. Stephens reaffirmed an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a report on Thursday, January 2nd. JPMorgan Chase & Co. raised their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Finally, Scotiabank started coverage on shares of Blueprint Medicines in a report on Friday, March 7th. They set a "sector outperform" rating and a $150.00 price target for the company. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $124.95.

Blueprint Medicines Stock Down 0.3 %

Shares of NASDAQ:BPMC traded down $0.27 during midday trading on Thursday, hitting $83.92. The stock had a trading volume of 521,528 shares, compared to its average volume of 768,385. The company has a market cap of $5.36 billion, a P/E ratio of -77.73 and a beta of 0.75. Blueprint Medicines has a 12 month low of $73.04 and a 12 month high of $121.90. The business's 50-day simple moving average is $88.22 and its 200-day simple moving average is $93.24. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15.

Insider Buying and Selling at Blueprint Medicines

In other news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the transaction, the chief operating officer now directly owns 69,266 shares in the company, valued at approximately $6,581,655.32. The trade was a 3.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares of the company's stock, valued at approximately $1,692,167.40. This represents a 14.92 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.21% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. R Squared Ltd purchased a new stake in Blueprint Medicines during the fourth quarter valued at about $51,000. Headlands Technologies LLC purchased a new stake in Blueprint Medicines in the fourth quarter worth approximately $65,000. Thematics Asset Management bought a new position in Blueprint Medicines during the fourth quarter valued at approximately $72,000. Covestor Ltd lifted its holdings in shares of Blueprint Medicines by 62.7% in the 4th quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 375 shares during the last quarter. Finally, Asset Management One Co. Ltd. purchased a new position in Blueprint Medicines in the 4th quarter worth $88,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.